Viridian Therapeutics Cash Per Share vs. Market Capitalization

VRDN Stock  USD 24.26  0.47  1.98%   
Based on Viridian Therapeutics' profitability indicators, Viridian Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in November. Profitability indicators assess Viridian Therapeutics' ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
10.66618106
Current Value
14.55
Quarterly Volatility
13.44480207
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Viridian Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 18th of October 2024, EV To Sales is likely to grow to 2,986, while Days Sales Outstanding is likely to drop 72.68. At this time, Viridian Therapeutics' Net Income Per E B T is very stable compared to the past year.
For Viridian Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Viridian Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Viridian Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Viridian Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Viridian Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.25)
Revenue Per Share
0.005
Return On Assets
(0.33)
Return On Equity
(0.54)
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Viridian Therapeutics Market Capitalization vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Viridian Therapeutics's current stock value. Our valuation model uses many indicators to compare Viridian Therapeutics value to that of its competitors to determine the firm's financial worth.
Viridian Therapeutics is rated first in cash per share category among its peers. It is rated first in market capitalization category among its peers creating about  333,746,454  of Market Capitalization per Cash Per Share. At this time, Viridian Therapeutics' Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viridian Therapeutics' earnings, one of the primary drivers of an investment's value.

Viridian Market Capitalization vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Viridian Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
5.66 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Viridian Therapeutics

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
1.89 B
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Viridian Market Capitalization vs Competition

Viridian Therapeutics is rated first in market capitalization category among its peers. Market capitalization of Health Care industry is at this time estimated at about 2.07 Billion. Viridian Therapeutics totals roughly 1.89 Billion in market capitalization claiming about 91% of equities under Health Care industry.
Capitalization  Valuation  Revenue  Workforce  Total debt

Viridian Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Viridian Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Viridian Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Viridian Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Viridian Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income338 K354.9 K
Operating Income-254.4 M-241.7 M
Income Before Tax-237.7 M-225.8 M
Total Other Income Expense Net16.7 M17.6 M
Net Loss-237.7 M-225.8 M
Income Tax Expense18.6 M19.5 M
Net Loss-116.9 M-111 M
Net Interest Income15.4 M16.1 M
Interest Income16.5 M17.3 M
Net Loss-216.7 M-205.8 M
Non Operating Income Net Other5.4 M5.7 M
Change To Netincome22.7 M20.2 M
Net Loss(5.31)(5.58)
Income Quality 0.77  0.76 
Net Income Per E B T 1.11  1.16 

Viridian Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Viridian Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Viridian Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Viridian Therapeutics' important profitability drivers and their relationship over time.

Use Viridian Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Viridian Therapeutics Pair Trading

Viridian Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Viridian Therapeutics position

In addition to having Viridian Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Management Thematic Idea Now

Management
Management Theme
Companies providing management services to businesses. The Management theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Management Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:
Check out World Market Map.
To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
To fully project Viridian Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Viridian Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Viridian Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Viridian Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Viridian Therapeutics investors may work on each financial statement separately, they are all related. The changes in Viridian Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Viridian Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.